Revenue increased to 686.0 (pro forma 586.2) MSEK in the full year 2020, corresponding to a growth of 17.0 %

Revenue amounted to 167.2 (184.2) MSEK in the fourth quarter, representing a decline of -9.2%. Adjusted EBITDA amounted to 12.2 (41.7) MSEK, representing a decline of -70.7%. Revenue recognition is negatively affected by the Covid-19 situation. Revenue during January - December amounted to 686.0 (20 Feb – 31 Dec, 2019; 518.9) MSEK. Adjusted EBITDA amounted to 156.1 (20 Feb -31 Dec 2019; 108.8) MSEK 

Revenue in the fourth quarter amounted to 167.2 (184.2) MSEK, representing a decline of -9.2%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional services revenue are attributable to the development of the existing product as well as the SUSSA project.

Adjusted EBITDA in the fourth quarter amounted to 12.2 (41.7) MSEK resulting in an adjusted EBITDA margin of 7.3 (22.6)%.

Employee related expenses amounted to 129.3 (118.1) MSEK, corresponding to an increase of 9.5%. The number of fulltime employees rose to 723 in the fourth quarter, an increase of 9.7% from the comparable figure last year. The number of employees by end of the fourth quarter amounted to 748 of which 371 were employed in Sweden and 326 were women.

Depreciation and amortization amounted to 36.3 MSEK, of which 27.6 MSEK refers to amortization of intangible assets with regards to M&A activities, 2.8 MSEK refers to financial leases and 3.0 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 2.9 MSEK.

Non-recurring items amounted to 15.1 MSEK, consisting of 5.3 MSEK relating to the introduction of a new ERP system, 4.8 MSEK relate to organisational adjustments and 5.0 MSEK relate to other.

Comments from Peter Gille, CEO

As a result of the spread of the Corona virus many people are living with challenging conditions and many have lost their lives.

The impact of Covid-19 on society and businesses continues to be severe. Cambio’s priorities under the current circumstances are to support our customers, to ensure our products fulfil their purpose without any interruptions and to protect the health and safety of our employees.

Cambio has, together with our existing customers, taken actions to directly address Covid-19 effects to make it possible to decrease administrative time, share information with municipalities, provide more intensive care beds and to offer the best vaccination record system available on the market.

Direct interactions with our customers remain in conjunction with the Covid-19 situation at a low level making it harder to sell new projects and obtain delivery approvals. We have also, seen negative impact on our operational efficiency and productivity. This has impacted some project timings and therefore revenue recognition. This is all in line with previous communication.

We have had intensive discussions with regions about Cambio´s vaccination solution MittVaccin. At the time of publishing this report 7 out of Cambio´s 17 regions have signed up to use MittVaccin.

We look forward to strengthening our position as a natural partner to our customers, to help them do their job more efficiently!

Please find the report here. For more information from Cambio, please visit cambiogroup.com.

This information is information that Sanolium AB(publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10 am CEST on 19 February 2021.

For further information, please contact: 

Fredrik Rüden, CFO +46 8 691 49 00 fredrik.ruden@cambio.se

Jenny Styren, CMCO +46 8 691 49 00 jenny.styren@cambio.se

SanoliumAB is the parent company in the CambioGroup, since February 20, 2019. The largest operating subsidiary in that group is Cambio Healthcare Systems whichwas founded in 1993 to deliver comprehensive IT-solutions for healthcare organizations. Today, Cambio is an e-health company providing smart, reliable, and user-friendly solutions to improve healthcare and patient safety with a market leading position in the Nordics including more than 100 000 users. We are committed to improve healthcare and patient safety

r